Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Delia Castellano Izquierdo: Innovator in Cardiotoxicity Prediction
Introduction
Delia Castellano Izquierdo is a notable inventor based in Valencia, Spain. She has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. Her innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Delia Castellano Izquierdo holds a patent for her invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA 192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.
Career Highlights
Throughout her career, Delia has worked with esteemed institutions such as Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. Her work has focused on advancing the understanding of cardiotoxicity in cancer treatments, which is crucial for improving patient care.
Collaborations
Delia has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to her research and the development of her innovative patent.
Conclusion
Delia Castellano Izquierdo is a pioneering inventor whose work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. Her contributions are vital for enhancing patient safety and treatment efficacy.